Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals shows a slight decrease today, losing -€0.200 (-0.930%) compared to yesterday.
Our community is currently high on Pacira Pharmaceuticals with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 30 € shows a positive potential of 40.19% compared to the current price of 21.4 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | -0.930% | -7.018% | -5.357% | 6.000% | -1.852% | -38.728% | -58.431% |
| Supernus Pharmaceuticals | 0.000% | -3.109% | -15.000% | 6.857% | -13.023% | 27.211% | 66.964% |
| Corcept Therapeutics Inc. | 0.940% | -3.486% | 17.777% | 54.317% | 40.099% | 242.143% | 426.374% |
| Collegium Pharmaceutical Inc | 0.000% | 0.654% | -1.911% | 4.762% | -25.604% | 42.593% | 79.070% |
Comments
Pacira BioSciences (PCRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (PCRX) had its price target raised by Needham & Company LLC from $30.00 to $32.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat